항응고제 중화제 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,635,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,087,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,990,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

항응고제 중화제 시장 성장 및 동향:

Grand View Research의 최신 보고서에 따르면, 세계 항응고제 중화제 시장 규모는 2030년까지 27억 8,000만 달러에 달할 것으로 예상됩니다.

2025년부터 2030년까지 연평균 12.3%의 CAGR로 성장할 것으로 예상됩니다. 출혈성 질환의 증가, 새로운 약물의 도입, 항응고 요법이 필요한 사례의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상되는 요인 중 일부입니다.

2015년 10월, 베링거인겔하임의 Praxbind(이달시주맙)는 응급 수술이나 다비가트란(다비가트란)으로 치료받은 환자 중 통제할 수 없거나 생명을 위협하는 출혈이 있을 때 사용할 수 있는 항응고제 중화제로 승인되었습니다. 따라서 이러한 항응고제 중화제가 출시됨에 따라 의사와 환자들은 더 많은 확신을 가지고 이러한 치료법을 고려할 수 있게 되어 항응고제 중화제에 대한 수요가 증가하고 있습니다.

혈우병과 같은 출혈성 질환은 후천적인 것과 유전적인 것이 있습니다. 그러나 다른 출혈성 질환은 HIV, 빈혈, 백혈병, 간경변증, 비타민 K 결핍증과 같은 질병으로 인해 발생할 수 있습니다. 미국 국립심폐혈액연구소에 따르면 미국에서는 300만 명 이상이 빈혈을 앓고 있으며, 이는 가장 흔한 혈액 질환입니다. 백혈병 림프종 협회(LLS)는 2020년에 약 60,530명이 백혈병 진단을 받을 것으로 예상된다고 밝혔습니다. 출혈성 질환의 증가는 항응고제에 대한 수요를 증가시켜 시장 성장에 박차를 가하고 있습니다.

그러나 이러한 항응고제는 고가이기 때문에 시장 성장을 억제할 것으로 예상됩니다. 미국심장학회(American College of Cardiology)에 따르면, 4-F PCC(Kcentra)는 리버록사반과 아픽사반으로 인한 출혈을 치료하는 데 도움이 되며, 50단위/kg으로 투여됩니다. 평균 도매가격은 1단위당 2.90달러로, 100kg의 환자를 치료하는 데 약 14,500달러가 소요됩니다.

항응고제 중화제 시장 보고서 하이라이트:

• 이달시주맙(idarucizumab) 부문은 2024년 36.8%의 매출 점유율을 차지하며 시장을 장악했습니다.
• 병원 약국이 2024년 매출 점유율 48.6%로 가장 큰 비중을 차지하며 시장을 장악하고 있습니다.
• 북미 항응고제 중화제 시장은 2024년 38.6%의 매출 점유율로 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항응고제 중화제 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 항응고제 중화제 시장 : 제품 유형별 비즈니스 분석

• 제품 유형 시장 점유율, 2024년 및 2030년
• 제품 유형 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 제품 유형별, 2018년에서 2030년
• 프로트롬빈 복합체 농축물
• Phytonadione(비타민 K)
• Andexanet Alfa
• Idarucizumab
• Protamine
• 기타

제5장 항응고제 중화제 시장 : 유통 채널별 비즈니스 분석

• 유통 채널 시장 점유율, 2024년 및 2030년
• 유통 채널 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 유통 채널별, 2018-2030년
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 항응고제 중화제 시장 : 지역 추정·동향 분석과 제품 유형 동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 항응고제 중화제 시장 : 유통 채널별 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 진출 기업 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/리스트
  • Pfizer Inc
  • AstraZeneca
  • Dr. Reddy's Laboratories Ltd
  • Endo International plc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan NV
  • Novartis AG.
  • Lupin
  • Cipla Inc

ksm

영문 목차

영문목차

Anticoagulant Reversal Drugs Market Growth & Trends:

The global anticoagulant reversal drugs market size is expected to reach USD 2.78 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 12.3% from 2025 to 2030. The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period.

In October 2015, Praxbind (idarucizumab) by Boehringer Ingelheim Pharmaceuticals was approved as an anticoagulant reversal drug indicated for patients treated with Pradaxa (dabigatran) during emergency surgery or uncontrolled or life-threatening bleeding. Hence, the availability of these anticoagulation reversal drugs allows doctors and patients to consider such treatment options with greater confidence, therefore boosting the demand for anticoagulant reversal drugs.

Bleeding disorders like hemophilia can be acquired or inherited. However, other bleeding disorders can occur from conditions, such as HIV, anemia, leukemia, cirrhosis of the liver, and vitamin K deficiency. According to the National Heart, Lung, and Blood Institute, more than 3 million people in the U.S. are affected with anemia, which is the most common blood disorder. The Leukemia & Lymphoma Society (LLS) stated that in the year 2020, the number of people expected to be diagnosed with leukemia is around 60,530. A rise in bleeding disorders is increasing the demand for anticoagulants, thus fueling the market growth.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Anticoagulant Reversal Drugs Market Report Highlights:

• The idarucizumab segment dominated the market, with a revenue share of 36.8% in 2024, driven by its high specificity for dabigatran as an effective option for reversing anticoagulation in emergencies.
• Hospital pharmacies dominated the market with the largest revenue share of 48.6% in 2024, driven by the need for immediate access to anticoagulant reversal agents in emergencies.
• North America anticoagulant reversal drugs market dominated the global market with a revenue share of 38.6% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Anticoagulant Reversal Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Anticoagulant Reversal Drugs Market: Product Type Business Analysis

• 4.1. Product Type Market Share, 2024 & 2030
• 4.2. Product Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
• 4.4. Prothrombin Complex Concentrates
  • 4.4.1. Prothrombin Complex Concentrates Market, 2018 - 2030 (USD Million)
• 4.5. Phytonadione (Vitamin K)
  • 4.5.1. Phytonadione (Vitamin K) Market, 2018 - 2030 (USD Million)
• 4.6. Andexanet Alfa
  • 4.6.1. Andexanet Alfa Market, 2018 - 2030 (USD Million)
• 4.7. Idarucizumab
  • 4.7.1. Idarucizumab Market, 2018 - 2030 (USD Million)
• 4.8. Protamine
  • 4.8.1. Protamine Market, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Anticoagulant Reversal Drugs Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacy
  • 5.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacy
  • 5.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 5.6. Online Pharmacy
  • 5.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Product Type

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Distribution Channel

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Pfizer Inc
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. AstraZeneca
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Dr. Reddy's Laboratories Ltd
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Endo International plc
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Teva Pharmaceutical Industries Ltd
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Sun Pharmaceutical Industries Ltd
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Mylan N.V.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Novartis AG.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Lupin
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Cipla Inc
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료